An observational study in Cervical Spondylotic Myelopathy, sponsored by Peking University Third Hospital. Status unknown. Per ClinicalTrials.gov, last updated 2021-07-08.
Sponsored by Peking University Third Hospital · Observational
Utilization of T2* MRI in predicting prognosis in patients with cervical spondylotic myelopathy (CSM)
Cervical spondylotic myelopathy (CSM), an age-related degenerative disease that is common worldwide, is mainly caused by compression of the spinal cord and may possibly lead to disability. Surgery to reduce direct compression of the spinal cord might alleviate disease progression; due to individual differences, some patients do not benefit from surgery. Prognostic prediction is important because it affects subsequent treatment decision making. Currently, prognosis is generally based on magnetic resonance imaging (MRI) with a detailed macrostructural evaluation of the spinal cord. Unfortunately, the use of conventional MRI indicators (e.g., increased intensity signal [ISI]) to predict CSM outcomes has been controversial because of their subjectivity or the insufficient information contained therein.
A new biomarker, T2* MRI gray matter to white matter signal intensity ratio (GM/WM), is associated with demyelination and gliosis. Previous studies have shown that patients with CSM can have T2* MRI WM / GM changes at the early stage of disease, and the WM / GM value is increased, which is significantly higher than that of normal people, and is related to the spinal cord function score. However, the correlation between this index and long-term prognosis remains to be studied.
200 studies on the registry are indexed under Spinal Cord Diseases; 51 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 57 observational studies indexed under Spinal Cord Diseases.
Browse Spinal Cord Diseases studies →Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients came from Peking University Third Hospital
Exclusion Criteria:
preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
Other: MRI
preoperative mJOA score 13\~14
Other: MRI
preoperative mJOA score ≤12
Other: MRI
T2\* MRI
Improvement of neurologic function
Postoperative modified Japanese Orthopaedic Association (mJOA) at follow-up time
Time frame: at follow-up time (≥1 years)
No study locations are listed for this record.
Plan to share: No — No.
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital